Last year, Cardiff, U.K.-based Verona secured £44.7 million ($65.6 million) from big-name investors on both sides of the Atlantic for work on its PDE3/PDE4…

Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.

Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.

Arriving later to the PCSK9 inhibitor market could actually be beneficial to Alnylam and The Medicines Company, say analysts.

When it comes to predicting who’s at risk of suffering a heart attack or other major cardiac event, physicians have long relied on detecting high levels of C-…

Eli Lilly was hit earlier this month when rival Novartis became the second, after front-runner Pfizer, to gain FDA approval for its CDK 4/6 inhibitor Kisqali (…

Fierce 15 winner CytomX is in line for a $200 million upfront payday and potentially billions in biobucks from partner Bristol-Myers Squibb as the Big Pharma…